

Pedram Razavi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9209468/publications.pdf>

Version: 2024-02-01

52
papers

9,991
citations

186265

28
h-index

175258

52
g-index

56
all docs

56
docs citations

56
times ranked

16734
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
2	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
3	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	16.8	633
4	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	30.7	485
5	Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , 2018, 50, 1189-1195.	21.4	411
6	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. <i>Cancer Cell</i> , 2018, 34, 893-905.e8.	16.8	307
7	Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists. <i>Cancer Discovery</i> , 2017, 7, 277-287.	9.4	286
8	Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018, 8, 174-183.	9.4	275
9	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
10	PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K \pm Inhibition. <i>Cancer Cell</i> , 2016, 30, 229-242.	16.8	187
11	Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3K \pm inhibitors. <i>Science</i> , 2019, 366, 714-723.	12.6	185
12	HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	9.4	149
13	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. <i>Nature Medicine</i> , 2019, 25, 1422-1427.	30.7	144
14	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. <i>Nature Genetics</i> , 2020, 52, 198-207.	21.4	140
15	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. <i>Cancer Discovery</i> , 2016, 6, 1134-1147.	9.4	106
16	KMT2C mediates the estrogen dependence of breast cancer through regulation of ER \pm enhancer function. <i>Oncogene</i> , 2018, 37, 4692-4710.	5.9	102
17	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 244-254.	2.8	96
18	Shift Work, Chronotype, and Melatonin Rhythm in Nurses. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1177-1186.	2.5	96

#	ARTICLE	IF	CITATIONS
19	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	13.2	96
20	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	12.8	68
21	INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. <i>Cancer Discovery</i> , 2022, 12, 356-371.	9.4	68
22	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 534-550.e9.	16.8	67
23	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. <i>JAMA Oncology</i> , 2020, 6, 84.	7.1	66
24	A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2020, 22, 57.	5.0	63
25	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). <i>Science Signaling</i> , 2018, 11, .	3.6	53
26	Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. <i>Nature Medicine</i> , 2022, 28, 946-957.	30.7	50
27	HER2+ breast cancers evade anti-HER2 therapy via a switch in driver pathway. <i>Nature Communications</i> , 2021, 12, 6667.	12.8	47
28	Metabolic Imaging Detects Resistance to PI3K± Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 516-533.e9.	16.8	38
29	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 53.	5.2	27
30	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	8.2	26
31	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. <i>Modern Pathology</i> , 2022, 35, 193-201.	5.5	25
32	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. <i>Clinical Cancer Research</i> , 2020, 26, 3720-3731.	7.0	21
33	Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. <i>Journal of Oncology</i> , 2017, 2017, 1-5.	1.3	20
34	Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K± Inhibitors. <i>Cancer Research</i> , 2021, 81, 2470-2480.	0.9	20
35	Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 307-317.	2.8	19
36	Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy. <i>JAMA Network Open</i> , 2021, 4, e2034045.	5.9	19

#	ARTICLE	IF	CITATIONS
37	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. <i>Nature Communications</i> , 2019, 10, 4369.	12.8	18
38	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021, 159, 66-73.	2.0	17
39	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 43.	5.2	16
40	Liquid biopsies for residual disease and recurrence. <i>Med</i> , 2021, 2, 1292-1313.	4.4	15
41	10-Year Breast Cancer Outcomes in Women ≥35 Years of Age. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1007-1018.	0.8	14
42	Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1009-1009.	1.6	13
43	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. <i>Clinical Cancer Research</i> , 2022, 28, 404-413.	7.0	13
44	Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 44.	5.2	11
45	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. <i>Investigational New Drugs</i> , 2017, 35, 742-750.	2.6	10
46	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. <i>Modern Pathology</i> , 2019, 32, 81-87.	5.5	10
47	Regional Lymph Node Involvement Among Patients With De Novo Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2020, 3, e2018790.	5.9	10
48	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. <i>Genome Medicine</i> , 2020, 12, 78.	8.2	10
49	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β -Catenin Signaling. <i>Molecular Cancer Research</i> , 2021, 19, 573-584.	3.4	10
50	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	5.2	9
51	Next-generation assessment of human epidermal growth factor receptor 2 gene (<i>ERBB2</i>) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline. <i>Histopathology</i> , 2021, 78, 498-507.	2.9	7
52	The Impact of PIK3R1 Mutations and Insulin-PI3K Glycolytic Pathway Regulation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3603-3617.	7.0	7